Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Auerbach

Dermatology Santa Fe, NM Medical Doctor

NPI 1154426427 CMS profile 98111

5 Calle Medico Ste A, Santa Fe, NM 87505

Open in the dashboard

General payments

$446

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Auerbach of Santa Fe, NM is reported in the CMS Open Payments database as having received $446 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 13
2023 General $19 1
2021 General $49 3
2020 General $39 2
2019 General $92 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Auerbach
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to James Auerbach were reported at $247. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year James Auerbach Dermatology median Middle half National median
2019 $92 $454 $129–$1,240 $163
2020 $39 $235 $81–$756 $114
2021 $49 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $19 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $247 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $169 9 payments
  2. Janssen Biotech, Inc. $51 2 payments
  3. Biofrontera Inc. $43 2 payments
  4. Novartis Pharmaceuticals Corporation $32 2 payments
  5. Organon LLC $31 2 payments
  6. LEO Pharma Inc. $29 1 payment
  7. Galderma Laboratories, L.P. $26 2 payments
  8. Kyowa Kirin, Inc. $19 1 payment
  9. Sun Pharmaceutical Industries Inc. $19 1 payment
  10. UCB, Inc. $14 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $446 24 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $117 6 payments
  2. TREMFYA $51 2 payments
  3. HUMIRA $40 2 payments
  4. ANZUPGO $29 1 payment
  5. POTELIGEO $19 1 payment
  6. Ameluz $19 1 payment
  7. BLU-U $19 1 payment
  8. Odomzo $19 1 payment
  9. NEMLUVIO $15 1 payment
  10. Rhapsido $15 1 payment
  11. Other $44 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,035

Median for Dermatology: 534

Drug cost

$163,171

Median for Dermatology: $67,151

Branded share of claims

4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Pen Adalimumab Brand 11 $73,560
Dupixent Pen Dupilumab Brand 18 $62,906
Tretinoin Generic 59 $5,435
Ketoconazole Generic 284 $5,201
Doxycycline Hyclate Generic 115 $4,056
Clobetasol Propionate Generic 89 $2,670
Famciclovir Generic 52 $2,108
Spironolactone Generic 64 $2,076
Triamcinolone Acetonide Generic 163 $2,062
Metronidazole Generic 29 $1,569

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$350,065

Of which drugs: $3,762

Medicare patients

1,269

Average age 77

Services billed

10,415

711 women, 558 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 49%
High blood pressure 48%
Osteoporosis 23%
Ischemic heart disease 18%
Cancer 16%
Diabetes 14%
Chronic kidney disease 14%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 13 13 $3,759

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record